VERISILICON
9.4.2024 09:01:28 CEST | Business Wire | Press release
VeriSilicon (688521.SH) today announced its demonstration at Embedded World 2024 in Nuremberg, Germany, booth numbered Hall 4A-518, where it is showcasing customers’ various leading products leveraging the company’s latest technologies and advanced solutions.
VeriSilicon’s one-stop custom silicon services and semiconductor IP licensing services provide customers with intelligent, secure, and highly adaptable solutions, addressing a wide range of key areas such as Artificial Intelligence (AI) and Machine Learning, Internet of Things (IoT), Consumer Electronics and Smart Devices, Data Center and High-Performance Computing, Smart Healthcare, and Automotive Electronics. Highlighted demonstrations include:
- AI and Machine Learning: A high-performance AI-PC with Blue Ocean’s chiplet acceleration card using GPGPU and NPU IPs powered by VeriSilicon, Google Open Se Cura powered by VeriSilicon, Inuitive vision AI processor featuring VeriSilicon’s dual-channel Image Signal Processor (ISP) IP.
- IoT: VeriSilicon’s LE Audio compliant complete Bluetooth Low Energy IP solution, LE Mesh system solution based on VeriSilicon’s BLE technology.
- Consumer Electronics and Smart Devices: A next-generation 8K TV and a leading Smart Camera integrated with VeriSilicon’s Neural Network Processor (NPU) IP, a next-generation Drone featuring VeriSilicon’s Video Processor Unit (VPU) IP, Smart Watches and Smart AR Glasses based on VeriSilicon’s Graphics Processor Unit (GPU) IP and Display Processor IP, Smart Home devices embedded with VeriSilicon’s IPs.
- Data Center and High-Performance Computing: VeriSilicon’s second-generation data center video transcoding platform solution.
- Smart Healthcare: VeriHealthi health monitoring platform based on VeriSilicon’s ZSP Digital Signal Processor (DSP) and BLE IPs.
- Automotive Electronics: Automotive SoC enabled by VeriSilicon’s ISO 26262 compliant IPs and subsystems.
VeriSilicon’s semiconductor IP licensing business holds the largest market share in China and ranks seventh worldwide1. Among the top ten IP companies globally, VeriSilicon’s number of IP categories ranks top two2. With over two decades of expertise in the GPU sector, VeriSilicon’s GPU IP has been shipped in nearly two billion chips. Additionally, VeriSilicon’s self-developed NPU IP has been integrated into 128 AI SoCs supplied by 72 licensees in more than 10 market segments, and has been shipped in over 100 million AI-enabled chips worldwide. In terms of video processing, VeriSilicon’s first-generation video transcoding acceleration solution, which is integrated with the company’s VPU IP, provides 6 times the transcoding capability of traditional high-end CPUs while consuming only 1/13 of the power. This innovative technology has been successfully applied to media accelerator chips custom-made for leading global chip companies based on the 5nm process and has entered the mass production stage.
As part of the Embedded World conference program, VeriSilicon’s Vice President of Vision Image Product Shang-Hung Lin will deliver a keynote speech themed Implementing Transformer Neural Networks for Visual Perception on Embedded Devices during Session 7.8 on Embedded Vision & Edge AI, scheduled for April 10 at 1:45pm.
“We are thrilled to present our latest and innovative IP solutions at Embedded World 2024. Our comprehensive Glass-to-Glass (from camera-in to display-out) intelligent pixel processing IP portfolio is silicon-proven, production-proven, and application-proven, which is configurable for a wide range of applications, ranging from low-power-focused to high-performance data center uses,” said Wei-Jin Dai, Executive VP and GM of IP Division at VeriSilicon. “In addition to our own IP offerings, we have also collaborated with third-party partners such as RISC-V IP providers and GUI software providers to deliver competitive solutions to our customers. Our commitment to IP innovations is aimed at empowering our customers’ success, enabling them to introduce innovative products to the market more quickly.”
To experience live demos and engage with VeriSilicon’s experts, please visit our booth at Messezentrum Nürnberg (Booth No.: Hall 4A-518) or schedule a meeting with us via email at eu-sales@verisilicon.com.
1 According to IPnest, April 2023
2 According to IPnest’s IP categorization and companies’ disclosure information
About VeriSilicon
VeriSilicon is committed to providing customers with platform-based, all-around, one-stop custom silicon services and semiconductor IP licensing services leveraging its in-house semiconductor IP. For more information, please visit: www.verisilicon.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240409713011/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom